Pharma Legal, Enforcement & Alert Intelligence
Source-linked judgments, compliance and enforcement developments, and regulatory alerts.
Court Judgments & Legal Opinions
Pharma-related cases, judgments, legal opinions and precedents.
148 recordsOpen Section →02
Compliance & Enforcement
Compliance requirements, inspections, violations, enforcement actions and recalls.
27 recordsOpen Section →03
Legal / Regulatory Alerts
Important legal and regulatory developments requiring attention.
503 recordsOpen Section →
Court Judgments & Legal Opinions · 148 visible records
High Courts of India
Jayan K. K. v. Drugs Inspector
Summary: The Kerala High Court considered the statutory protection claimed by a stockist who purchased drugs from an authorised source and asserted proper storage without knowledge of a quality contravention.
Outcome / action: The revision was allowed, the discharge order was set aside and the Magistrate was directed to reconsider the stockist’s application specifically under the statutory Section 19(3) defence.
Practical impact: Stockists should retain licensed-source invoices and storage evidence; courts must assess all three Section 19(3) conditions when the defence is properly raised.
Open source record →Dr. Rajesh Kumar Gupta v. State of Uttarakhand & Another
Summary: The Uttarakhand High Court reviewed large quantities of Phenobarbital and Chlordiazepoxide kept at a clinic and the interaction of medical-use exemptions with NDPS liability.
Outcome / action: The quashing application was dismissed because entitlement to medical-use and Schedule K exemptions for commercial quantities of psychotropic drugs required licence, patient and transaction evidence at trial.
Practical impact: Medical purpose alone is insufficient: clinics must retain licences, purchase records, patient registers, prescriptions and compliant storage evidence for controlled medicines.
Open source record →Supreme Court of India
Miteshbhai J. Patel & Another v. Drug Inspector & Another
Summary: The Supreme Court examined limitation in prosecutions concerning two batches of Rabeprazole tablets reported not of standard quality.
Outcome / action: The appeals were allowed, the Kerala High Court judgment was set aside and the complaints were quashed because they were filed beyond the three-year limitation period without a plea seeking condonation or exclusion of time.
Practical impact: Drug inspectors should institute complaints within limitation or place a legally supported delay-condonation request before the court instead of relying on administrative collection time.
Open source record →Shailyamanyu Singh v. State of Maharashtra
Summary: The Supreme Court considered whether a non-executive director could be prosecuted for expired Vicks Multi Pain Relief Gel found with an unlicensed downstream entity.
Outcome / action: The appeal was allowed and criminal process against the non-executive director was quashed because the complaint did not provide a specific factual basis showing operational responsibility, consent, connivance or neglect.
Practical impact: Complaints must connect each officer to the alleged contravention through specific responsibilities or conduct; designation alone is insufficient.
Open source record →Other Courts & Tribunals
M/s Vardhman Exports v. United India Insurance Co. Ltd.
Summary: The National Commission considered damage to Diethylcarbamazine Citrate tablets during transit and the evidentiary distinction between hygroscopic moisture damage and an inherent product defect.
Outcome / action: The appeal and complaint were allowed; the insurer was directed to indemnify the pharmaceutical consignment loss with interest and costs because inherent vice was not established.
Practical impact: Transit-quality disputes require defensible sampling, laboratory reasoning, storage and transport evidence; an unexplained NSQ conclusion may not establish an insurance exclusion.
Open source record →High Courts of India
Dharmendra Kumar v. State of Uttar Pradesh & Another
Summary: The Allahabad High Court reviewed whether police-led proceedings could continue for alleged Drugs and Cosmetics Act offences in light of the Act’s special prosecution mechanism.
Outcome / action: The application was allowed and the charge-sheet, cognizance, non-bailable-warrant order and entire proceedings were quashed.
Practical impact: Verify that investigation and institution of prosecution follow the special statutory route prescribed for Chapter IV offences.
Open source record →Maneesh Pharmaceuticals Ltd. v. State of Telangana
Summary: The Telangana High Court reviewed company and director liability in a prosecution concerning Doxyla-B6 reported not of standard quality.
Outcome / action: The petition was allowed and proceedings were quashed because the complaint did not contain specific allegations or supporting material connecting the company and director with manufacture of the alleged substandard drug.
Practical impact: A complaint should state the responsible officer’s actual manufacturing or business role and document service of the analyst report on the manufacturer.
Open source record →Dr. Rachna Jindal v. State of Uttar Pradesh & Another
Summary: The Allahabad High Court examined the maintainability of criminal proceedings combining Drugs and Cosmetics Act allegations with cheating.
Outcome / action: The application was allowed and proceedings under Sections 18(c) and 27 of the Act and Section 420 IPC were quashed.
Practical impact: Authorities should distinguish the Act’s special complaint mechanism from independently supportable general penal offences.
Open source record →M/s Neptune Life Science (P) Ltd. & Others v. Union of India
Summary: The Himachal Pradesh High Court examined the minimum reasoning required when a Magistrate summons a pharmaceutical company and its officers.
Outcome / action: The petition was allowed and the summoning order was set aside because it was non-speaking and did not demonstrate the Magistrate’s application of mind; the Magistrate was directed to reconsider process in accordance with law.
Practical impact: A process order need not be lengthy, but it must show consideration of the complaint, supporting material and the alleged role of each accused.
Open source record →M/s Health Biotech Ltd. & Others v. State of Rajasthan
Summary: The Rajasthan High Court examined vicarious liability, statutory sampling and retesting safeguards, and procedural compliance in a prosecution involving an allegedly substandard drug.
Outcome / action: The petitions were allowed and the cognizance order and consequential proceedings were quashed, including on findings concerning missing Section 34 responsibility, procedural defects and loss of the retesting safeguard.
Practical impact: Complaints should identify the actual responsibility of company officers and preserve timely retesting rights before shelf-life expiry.
Open source record →Shri Aatmaram Vidhwani v. State of Madhya Pradesh
Summary: The Madhya Pradesh High Court considered whether a trade-named cream containing Mometasone Furoate was a drug and whether a cosmetic tick in the sampling form defeated prosecution.
Outcome / action: The quashing petition was dismissed because Kaylite cream contained a Schedule H drug and the broad statutory definition and proprietary-medicine standards supported continuation of the unlicensed-storage and NSQ prosecution.
Practical impact: Product trade names and clerical form errors do not control classification; composition, intended use, labelling and statutory quality standards do.
Open source record →M/s Panjon Pharma Limited v. State of Rajasthan
Summary: The Rajasthan High Court considered a manufacturer’s right to receive the analyst report and seek Central Drugs Laboratory testing before the sampled drug expired.
Outcome / action: The petition was allowed and the complaint proceedings were quashed against the petitioners because delayed communication deprived the manufacturer of the Sections 25(3) and 25(4) retesting remedy; proceedings against other accused continued.
Practical impact: Authorities should communicate analyst reports early enough to preserve the manufacturer’s effective statutory retesting opportunity.
Open source record →Lala Mohd. Hanif Mohd. Umar & Others v. State of Maharashtra through Drug Inspector
Summary: The Bombay High Court considered whether licence suspension and later prosecution for allegedly NSQ PEL APS tablets constituted double jeopardy.
Outcome / action: The application was rejected; prior administrative suspension of the manufacturing licence was not a criminal prosecution or judicial punishment and therefore did not bar the NSQ prosecution as double jeopardy.
Practical impact: Administrative licence action and criminal prosecution are distinct; Article 20(2) generally requires an earlier prosecution and judicial punishment for the same offence.
Open source record →M/s Hindustan Syringes and Medical Devices Ltd. & Others v. Drugs Inspector
Summary: The Madras High Court reconsidered an NSQ prosecution and the manufacturer’s claim that its statutory right to Central Laboratory retesting had been lost.
Outcome / action: After rehearing, the Court rejected the challenge to prosecution; the manufacturer had received the report and sample portion but had not timely invoked the statutory Central Drugs Laboratory process.
Practical impact: A manufacturer disputing an analyst report should issue a clear timely notice and promptly seek Central Drugs Laboratory testing through the prescribed statutory route.
Open source record →Virendra Sharma v. State of Jharkhand
Summary: The Jharkhand High Court examined whether a complaint against an unnamed “Director” and an unaddressed reanalysis request could sustain criminal process.
Outcome / action: The petition was allowed and proceedings were quashed against the named petitioner because the complaint had proceeded against a designation, reanalysis was not considered before expiry and the Section 202 CrPC safeguard was not followed.
Practical impact: Name the accused legal person, state the individual role and complete territorial-jurisdiction inquiry and retesting steps before issuing process.
Open source record →Subhash Nair v. State of Jharkhand
Summary: The Jharkhand High Court considered prosecution of a quality-control manager concerning Megapen capsules reported not of standard quality.
Outcome / action: The petition was allowed and proceedings were quashed against the petitioner because the requested CDL reanalysis was not considered, the drug had long expired and the mandatory Section 202 CrPC inquiry was omitted.
Practical impact: Courts should decide timely reanalysis requests and conduct the required inquiry before summoning an accused residing outside territorial jurisdiction.
Open source record →Assam Pharmacy Council & Another v. State of Assam & Others
Summary: The Gauhati High Court examined the separate powers of Drugs Inspectors and Pharmacy Council Inspectors and the State’s duty to frame rules for Pharmacy Act inspections.
Outcome / action: The Court held that Drugs and Cosmetics Act inspectors could not exercise Pharmacy Act inspector powers, set aside the contrary State communication and directed the State to address the distinct statutory inspector framework.
Practical impact: Regulatory inspections must be performed by officers appointed and empowered under the correct statute; overlapping health-regulation roles are not interchangeable.
Open source record →Mithilesh Yadav v. State of Bihar
Summary: The Patna High Court examined the transitional treatment of police-investigated Drugs and Cosmetics Act cases initiated before the Supreme Court clarified Drug Inspector primacy.
Outcome / action: The Court declined to interfere with the cognizance-stage prosecution because the pre-Ashok Kumar Sharma police investigation and completed cognizance fell within the saving directions issued by the Patna High Court Special Bench.
Practical impact: For legacy prosecutions, verify the FIR, investigation and cognizance dates against the applicable saving directions before asserting that police involvement invalidates the case.
Open source record →M/s Micro Labs Ltd. Unit III v. Union of India
Summary: The Madhya Pradesh High Court reviewed proceedings involving Thyrotop 100 tablets and the manufacturer’s lost opportunity for timely testing and analysis.
Outcome / action: The petition was allowed and prosecution in Special Complaint Case No. 88/2020 was quashed because the statutory testing and defence opportunity could no longer be meaningfully exercised before shelf-life expiry.
Practical impact: Testing notices, sample portions and prosecution should progress quickly enough to preserve the statutory challenge mechanism.
Open source record →Other Courts & Tribunals
National Insurance Company Ltd. v. M/s S.S. Pharma
Summary: The National Commission assessed a fire-loss claim for pharmaceutical stocks and whether the insurer’s survey report justified restricting the claim.
Outcome / action: The appeal was disposed of with modification: the insurer remained liable for the insured pharmaceutical stock loss with interest, while the separate compensation award was removed.
Practical impact: Pharmaceutical businesses should preserve inventory, purchase and fire-loss evidence; a survey report may be rejected when contradicted by stronger investigation and fire-service material.
Open source record →